FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with it
On Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name Spravato) nasal spray as a "monotherapy" treatment for major depressive disorder. The drug was first approved for in 2019 but patients also to be taking an antidepressant at the same time. Now, esketamine can…
Keep reading with a 7-day free trial
Subscribe to Boing Boing to keep reading this post and get 7 days of free access to the full post archives.